MDM2 overexpression accounted for 20% of BC patients, which is particularly helpful in promoting the progression of HR-positive BC.[19] CDK4/6i resistant cells have been reported to disrupt the aging pathway and to be insensitive to induction of aging. This evidence concerns the gene MDM2 and breast cancer.